Related Experiment Video
Updated: Feb 14, 2026

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
Published on: October 16, 2010
Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis
Mha de Lima1, Gnm Hajj2, Vcc de Lima3
1Stomatology Department, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Abstract:
A total of 115 patients who used everolimus were evaluated. The mean age was 57 (±13.3) years old, and 87 patients were women (75.6%). mTOR inhibitor-associated stomatitis (mIAS) was observed in 36 patients (31.3%). The lesions ranged from 0.5 cm to 1.5 cm, and the tongue was the main site affected. In addition, 21 patients (58.3%) required a dose reduction of everolimus due to mIAS. Patients who had breast cancer presented 2.29-fold higher risk for developing mIAS when compared to patients with kidney or neuroendocrine tumors. This study emphasizes the high prevalence of mIAS in patients using everolimus, in particular, in patients with breast cancer.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
PI3K/mTOR/AKT Signaling Pathway
Increasing Function
Relative Risk
Increased Body Temperature

